Table 2.

Summary of clinical trials involving CTAs with a focus on breast cancer.

Target	Clinical Trials.Gov Identifier	Type	Drug Details	Phase	Recruitment Status	Breast Cancer Subtypes/Other Cancers
NY-ESO-1	NCT03093350	T-cell immunotherapy	Tumour-associated antigen (TAA)-specific cytotoxic T- lymphocytes targeting NY-ESO-1, MAGEA4, PRAME, survivin and SSX2	Phase II	Active, not recruiting	Metastatic or locally recurrent unresectable breast cancer
	NCT02015416	Cancer vaccine	IDC-G305: immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant GLA-SE	Phase I	Completed	Breast cancer, melanoma, ovarian cancer, sarcoma or NSCLC
	NCT01522820	Cancer vaccine	DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus	Phase I	Completed	Breast cancer, other solid tumours
	NCT00291473	Cancer vaccine	Cholesterol-bearing hydrophobized pullulan HER2 protein 146 (CHP-HER2) and NY-ESO-1 protein (CHP-NY-ESO-1) in combination with OK-432	Phase I	Completed	HER2- and/or NY-ESO-1-expressing cancers
	NCT01967823	T-cell immunotherapy	Anti-ESO mTCR-engineered peripheral blood lymphocytes with high-dose aldesleukin	Phase II	Completed	Metastatic cancer, including melanoma whose tumours express the ESO antigen
	NCT02661100	Cancer vaccine	CDX-1401: human monoclonal antibody specific for DEC-205, fused to full-length tumour antigen NY-ESO-1 in combination with poly-ICLC and pembrolizumab	Phase I/II	Withdrawn (Drug unavailable)	Advanced TNBC, NSCLC, small-cell lung cancer, urothelial cancer, mesothelioma, malignant melanoma
	NCT02457650	T-cell immunotherapy	Anti-NY-ESO-1 TCR transduced T cells	Phase I	Unknown	Breast cancer, other solid tumours
	NCT00623831	Cancer vaccine	mixed bacteria vaccine in patients with tumours expressing NY-ESO-1 antigen	Phase I	Completed	Breast cancer, other solid tumours
	NCT03159585	T-cell immunotherapy	TAEST16001: NY-ESO-1-specific TCR affinity enhancing specific T-cell therapy	Phase I	Completed	Breast cancer stage IV, other advanced solid tumours
	NCT01234012	Cancer vaccine	MF-001: CHP-NY-ESO-1 complex consisting of recombinant NY-ESO-1 protein and cholesteryl hydrophobized pullulan (CHP)	Phase I	Completed	Metastatic or refractory breast cancer, other solid tumours
	NCT00948961	Cancer vaccine	CDX-1401 with immune stimulants such as resiquimod and poly-ICLC (Hiltonol)	Phase I/II	Completed	Advanced malignancies expressing NY-ESO-1
MAGE	NCT04639245	T-cell immunotherapy	Genetically engineered cells (MAGE-A1-specific T-cell receptor-transduced autologous T cells) and atezolizumab	Phase I/II	Not yet recruiting	Metastatic TNBC, urothelial cancer or NSCLC
	NCT02153905	T-cell immunotherapy	Autologous T cells transduced with an anti-MAGE-A3 HLA-A*01-restricted TCR (MAGE-A3-01) TCR and aldesleukin	Phase I/II	Terminated	Breast cancer, cervical cancer, renal cancer, melanoma, bladder cancer
	NCT02111850	T-cell immunotherapy	HLA-DP0401/0402 restricted anti-MAGE-A3 TCR-gene engineered lymphocytes and aldesleukin	Phase I/II	Active, not recruiting	Breast cancer, cervical cancer, renal cancer, urothelial cancer, melanoma
	NCT00020267	Cancer vaccine	MAGE-12 peptide vaccine	Phase I	Completed	Refractory metastatic cancer expressing MAGE-12 antigen: Breast cancer, other solid tumours
	NCT03093350	T-cell immunotherapy	Tumour-associated antigen (TAA)-specific cytotoxic T- lymphocytes targeting NY-ESO-1, MAGEA4, PRAME, survivin and SSX2	Phase II	Active, not recruiting	Any breast cancer patient with metastatic or locally recurrent unresectable breast cancer
PRAME	NCT03093350	T-cell immunotherapy	Tumour-associated antigen (TAA)-specific cytotoxic T-lymphocytes targeting NY-ESO-1, MAGEA4, PRAME, survivin and SSX2	Phase II	Active, not recruiting	Any breast cancer patient with metastatic or locally recurrent unresectable breast cancer
	NCT00423254	Cancer vaccine	DNA vector pPRA-PSM with synthetic peptides, E-PRA and E-PSM	Phase I	Completed	Advanced solid malignancies: Breast cancer, other solid tumours
MSLN	NCT02792114	T-cell immunotherapy	Mesothelin-specific chimeric antigen receptor-positive T cells	Phase I	Recruiting	Breast cancer, metastatic HER2-negative breast cancer
	NCT02414269	T-cell immunotherapy	Mesothelin-targeted T cells	Phase I/II	Recruiting	Breast cancer, malignant pleural disease, mesothelioma, metastases, lung cancer
	NCT02580747	T-cell immunotherapy	Anti-meso-CAR vector transduced T cells	Phase I	Unknown	TNBC, other mesothelin-positive tumours
	NCT03102320	Antibody-drug conjugate	Anetumab–ravtansine: mesothelin-targeting antibody-drug conjugate	Phase Ib	Active, not recruiting	TNBC, cholangiocarcinoma, adenocarcinoma of the pancreas, NSCLC, gastric adenocarcinoma
	NCT02485119	Antibody-drug conjugate	BAY94-9343: anetumab– ravtansine	Phase I	Completed	Advanced malignancies
PSCA	NCT03927573	Antibody	GEM3PSCA: PSCA-targeted bispecific antibody engaging T cells	Phase I	Recruiting	PSCA-positive cancer: urogenital tract (renal, transitional cell, prostate), NSCLC, breast and pancreatic cancer refractory to standard treatments
ROR2	NCT03504488	Antibody-drug conjugate	Conditionally active biologic (CAB) ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC)	Phase I/II	Recruiting	TNBC, locally advanced unresectable or metastatic solid tumours that have failed all available standard therapies, NSCLC, soft tissue sarcoma
WT1	NCT01220128	Cancer vaccine	GSK2302024A: recombinant WT1 antigen-specific cancer immunotherapeutic (ASCI)	Phase II	Terminated (negative phase III of another study product from same technology platform)	WT1-positive stage II or III breast cancer
	NCT02018458	Cancer vaccine	Cyclin B1/WT-1/CEF (antigen)-loaded dendritic cell vaccination with preoperative chemotherapy	Phase I/II	Completed	TNBC, ER+/HER2-breast cancer
	NCT03761914	Cancer vaccine	Galinpepimut-S: WT1 analogue peptide vaccine	Phase I/II	Recruiting	TNBC, acute myelogenous leukaemia, ovarian cancer, colorectal cancer, small-cell lung cancer
	NCT01291420	Cancer vaccine	Autologous WT1 mRNA-transfected dendritic cell vaccine	Phase I/II	Unknown	Breast cancers, glioblastoma, renal cell carcinoma, sarcomas, malignant mesothelioma, colorectal tumours